These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 7513935)
1. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Jackman AL; Gibson W; Brown M; Kimbell R; Boyle FT Adv Exp Med Biol; 1993; 339():265-76. PubMed ID: 7513935 [TBL] [Abstract][Full Text] [Related]
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676 [TBL] [Abstract][Full Text] [Related]
3. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860 [TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates. Jackman AL; Marsham PR; Moran RG; Kimbell R; O'Connor BM; Hughes LR; Calvert AH Adv Enzyme Regul; 1991; 31():13-27. PubMed ID: 1877386 [TBL] [Abstract][Full Text] [Related]
5. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Hanlon MH; Ferone R Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125 [TBL] [Abstract][Full Text] [Related]
7. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism. Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737 [TBL] [Abstract][Full Text] [Related]
8. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Ward WH; Kimbell R; Jackman AL Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289 [TBL] [Abstract][Full Text] [Related]
9. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. Keyomarsi K; Samet J; Molnar G; Pardee AB J Biol Chem; 1993 Jul; 268(20):15142-9. PubMed ID: 8325888 [TBL] [Abstract][Full Text] [Related]
10. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479 [TBL] [Abstract][Full Text] [Related]
11. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Yin MB; Guimaraes MA; Zhang ZG; Arredondo MA; Rustum YM Cancer Res; 1992 Nov; 52(21):5900-5. PubMed ID: 1394217 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518 [TBL] [Abstract][Full Text] [Related]